All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “Targeting Protein Kinases and DNA Repair” took place.
One of the posters on display (4182 / 5) was titled “The two novel BTK-inhibitors M2951 and M7583 show in vivo anti-tumor activity in pre-clinical models of B cell lymphoma” by Eugenio Gaudio from the Institute of Oncology Research, Bellinzona, Switzerland, and colleagues.
This group aimed to evaluated the anti-tumor activity of M2951 and M7583 (two novel, highly selective, irreversible BTK inhibitors) in an in vivo ABC DLBCL model. Xenografts were established by SC injection of TMD8 cells (100µL of PBS, 107 cells/mouse) into the left flanks of female NOD-SCID mice. Treatments (QD, po) began with an average tumor volume of 100mm3 on groups of 10 mice each.
The poster concluded that M2951 and M7583 displayed encouraging anti-tumor activity in vivo in their ABC DLBCL murine model. The data supports further investigation of these compounds for the treatment of B-cell Lymphomas.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox